Flotetuzumab is an investigational CD123 dual-affinity retargeting antibody (DART) molecule (CD123 × CD3; MGD006) that simultaneously binds CD123 on target AML cells and CD3 on the effector T cells. This evidence concerns the gene IL3RA and acute myeloid leukemia.